Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on TRVI stock, giving a Buy rating yesterday.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Faisal Khurshid has given his Buy rating due to a combination of factors surrounding Trevi Therapeutics’ recent developments and promising data. The company hosted an investor event at the American Thoracic Society, where they presented encouraging updates on their Haduvio program, particularly following the Phase 2a RIVER study in refractory chronic cough. The new data reinforced Haduvio’s favorable profile, especially in terms of tolerability, which boosts confidence ahead of the upcoming Phase 2b CORAL data release.
Additionally, the analyses from the RIVER study provided deeper insights into the efficacy of Haduvio, highlighting its best-in-disease performance. These findings, coupled with the implementation of mitigation measures that have significantly reduced discontinuation rates, suggest a strong potential for positive outcomes in the CORAL study. Khurshid’s optimistic outlook is further supported by the expert panel discussions at the event, which underscored Haduvio’s promising future in addressing chronic cough and interstitial lung disease.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $24.00 price target.
TRVI’s price has also changed dramatically for the past six months – from $2.770 to $6.470, which is a 133.57% increase.